Biotechnology company Gilead Sciences (NASDAQ:GILD) wasn’t a “Magnificent Seven” company or a darling of the financial markets in 2023. Yet, GILD stock deserves a long-overdue rally in 2024. Gilead Sciences is doing important scientific work, and the company’s financials are fairly solid. Sure, weight-loss products deserve attention, but analysts and investors seem to be obsessing over them lately. Meanwhile, Gilead Sciences is making headway with critical, potentially lifesaving treatments. So, if you like ...